Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
DCOM$42.33+0.47(+1.12%)Dime Supports Local Moriches Bay Project[11:47:13 AM ET]NRSN$2.16-0.20(-8.47%)NeuroSense to Present Integrated Clinical and Biomarker Evidence Shaping PrimeC's Phase 3 Development at NEALS 2026 NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense" or the "Company"), a biotechnology company developing treatments for neurodegenerative...[11:30:00 AM ET]PRKS$31.61+0.61(+1.97%)BUSCH GARDENS' AWARD-WINNING CHRISTMAS TOWN RETURNS WITH MILLIONS OF LIGHTS, ALL-NEW ENTERTAINMENT AND FESTIVE FUN AT ITS TWO SPECTACULAR PARKS The most wonderful time of the year is almost here, and Busch Gardens Christmas Town™ is ready to make it brighter than ever. Beginning Nov. 13, both ...[11:30:00 AM ET]DYNC$10.96+0.06(+0.55%)Dynamix Corporation Announces Its Intention to Liquidate[11:30:00 AM ET]PRKS$31.61+0.61(+1.97%)SEAWORLD'S AWARD-WINNING CHRISTMAS CELEBRATION RETURNS IN ORLANDO, SAN DIEGO AND SAN ANTONIO WITH ALL-NEW FESTIVE ENTERTAINMENT AND TIMELESS HOLIDAY JOY The most wonderful time of the year is almost here, and SeaWorld is ready to shine. This holiday season, SeaWorld Orlando, SeaWorld San Diego and...[11:25:00 AM ET]CRVW$0.03+0.00(+8.92%)CareView Communications Announces New Business Agreement with San Juan Regional Medical Center[11:20:00 AM ET]ARAI$0.11+0.00(+1.63%)Arrive AI Installs First Arrive Point(TM) Units in Commercial Office Building in Central Indiana[11:11:00 AM ET]MGN$3.86+0.27(+7.52%)Megan Holdings Limited Announces Closing of $7.5 Million Follow-on Public Offering[11:10:00 AM ET]NIDB$24.74+0.22(+0.90%)NORTHEAST INDIANA BANCORP, INC. INCREASES QUARTERLY CASH DIVIDEND The Board of Directors of Northeast Indiana Bancorp, Inc., (OTCQB: NIDB), the parent company of First Federal Savings Bank, is proud to announce the...[11:10:00 AM ET]APPN$49.64-2.33(-4.47%)Appian Defense Cloud Achieves IL5 Authorization Across Department of War Operations Appian today announced that the Appian Defense Cloud (ADC) achieved Impact Level 5 (IL5) Provisional Authorization to Operate (PA) from the United...[11:00:00 AM ET]OSBC$24.62+0.21(+0.86%)O2 Sponsor Finance Hires James Benbrook as Vice President[11:00:00 AM ET]HOST$3.03+0.09(+3.24%)Before the Midterms, a Debate Over Where Data Centers Belong and Who Pays for Their Power[10:58:38 AM ET]

VVOS · NASDAQ

Vivos Therapeutics, Inc.

$0.12 0.00 (-2.95%)

Company overview

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. Vivos Therapeutics also offers the VivoScore Program, a screening and home sleep test for adults and children. The company markets and sells its Vivos System to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado.

Sector
Healthcare
Industry
Medical - Devices
Exchange
NASDAQ
Market cap
$1.7M
Employees
109
Headquarters
Highlands Ranch, CO
Website
vivos.com
CEO
R. Kirk Huntsman
Listed
December 11, 2020
P/E
-0.05
Dividend yield
0.00%

Company financials

Revenue
$19.6M
Gross profit
$11.6M
Operating income
-$22.6M
EBITDA
-$21M
Net income
-$25.1M
EPS
-$2.30
Total assets
$25M
Total debt
$12.3M
Gross margin
59.48%
Net margin
-128.36%
Earnings yield
-1,916.67%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

No geographic segmentation.

Showing FY 2025

Price chart

0.070.400.741.071.41
VVOS 1D NASDAQ O0.13H0.13L0.12C0.12-0.00 (-3.66%)Vol364.60K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
VVOSVivos Therapeutics, Inc. Press release CORRECTION: SOD Sciences Welcomes Vivos Therapeutics as Strategic Investor and Partner in the ReBalU Primed Cell Test ACCESS Newswire
VVOSVivos Therapeutics, Inc. Press release Vivos Therapeutics Reports Nasdaq Confirmation of Compliance with Continued Listing Shareholders’ Equity Standard GlobeNewswire
VVOSVivos Therapeutics, Inc. Press release SOD Sciences Welcomes Vivos Therapeutics as Strategic Investor and Partner in the ReBalU Primed Cell Test ACCESS Newswire
VVOSVivos Therapeutics, Inc. Press release Vivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA Channel GlobeNewswire
VVOSVivos Therapeutics, Inc. Press release Vivos Therapeutics Agrees to Acquire Minority Stake in SOD Sciences and 50% Interest in Proprietary Pseudohypoxia Test GlobeNewswire
VVOSVivos Therapeutics, Inc. Press release Vivos Therapeutics Reports Progress in Material Cost Reductions and Revenue Growth Initiatives GlobeNewsWire
VVOSVivos Therapeutics, Inc. Press release Vivos Therapeutics Announces Material Debt Reduction GlobeNewswire
VVOSVivos Therapeutics, Inc. Press release Vivos Therapeutics to Present at the 2026 Moody Capital Solutions Disruptive Growth & Life Sciences Conference Newsfile
VVOSVivos Therapeutics, Inc. Stock news Dow Falls Over 300 Points; SAIC Shares Jump After Upbeat Q2 Results Benzinga
VVOSVivos Therapeutics, Inc. Stock news Why Webuy Global Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket Benzinga
VVOSVivos Therapeutics, Inc. Press release Vivos Therapeutics and South Palm Cardiovascular Associates Sign Definitive Agreements to Launch Regional Sleep Testing and Treatment Center GlobeNewsWire
VVOSVivos Therapeutics, Inc. Press release Vivos Therapeutics Reports Record New Patient Referrals at its Nevada Sleep & Airway Medicine Centers GlobeNewsWire
VVOSVivos Therapeutics, Inc. Press release Vivos Therapeutics Opens New Sleep Testing and Treatment Facility in Nevada to Meet Rapidly Growing Patient Demand for Sleep Apnea Testing and Treatment GlobeNewsWire
VVOSVivos Therapeutics, Inc. Stock news Vivos Therapeutics, Inc. (VVOS) Reports Q2 Loss, Lags Revenue Estimates Zacks Investment Research
VVOSVivos Therapeutics, Inc. Stock news Vivos Therapeutics, Inc. (VVOS) Q2 2026 Earnings Call Transcript Seeking Alpha
VVOSVivos Therapeutics, Inc. Press release Vivos Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Update GlobeNewsWire
VVOSVivos Therapeutics, Inc. Press release Vivos Therapeutics Schedules Release of Second Quarter 2026 Financial Results and Conference Call GlobeNewsWire
VVOSVivos Therapeutics, Inc. Press release Vivos Therapeutics Announces Issuance of New US Patent Broadening Protection for Its Vivos CARE Oral Medical Device Technology GlobeNewsWire
VVOSVivos Therapeutics, Inc. Press release Vivos' Vida® Appliance Shows Statistically Significant Improvement in Insomnia Severity in 100% of Study Participants GlobeNewsWire
VVOSVivos Therapeutics, Inc. Press release Vivos Therapeutics and Streeterville Extend Timeframe of Strategic Financing Agreement and Reaffirm Commitment to Convert Debt Into Common Stock and Perpetual Preferred Equity GlobeNewsWire
See more
FAQ

Questions about Vivos Therapeutics, Inc.

What does Vivos Therapeutics, Inc. do?
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. Vivos Therapeutics also offers the VivoScore Program, a screening and home sleep test for adults and children. The company markets and sells its Vivos System to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado.
What is VVOS's market cap?
Vivos Therapeutics, Inc. (VVOS) is a listed stock with a live quote. The latest market cap on this page is $1.7M.
Where is Vivos Therapeutics, Inc. headquartered?
Vivos Therapeutics, Inc. is headquartered in Highlands Ranch, CO.
How do I get VVOS news from the API?
Call GET /v1/news?tickers=VVOS. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does VVOS news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for VVOS, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the VVOS price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs